Geron Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Geron şirketinin toplam hissedar öz sermayesi $292.3M ve toplam borcu $83.8M olup, bu da borç-öz sermaye oranını 28.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $445.0M ve $152.7M dir.

Anahtar bilgiler

28.7%

Borç/özkaynak oranı

US$83.84m

Borç

Faiz karşılama oranı	n/a
Nakit	US$339.77m
Eşitlik	US$292.28m
Toplam yükümlülükler	US$152.67m
Toplam varlıklar	US$444.95m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0IV3 'nin kısa vadeli varlıkları ( $398.1M ) kısa vadeli yükümlülüklerini ( $137.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0IV3 şirketinin kısa vadeli varlıkları ( $398.1M ) uzun vadeli yükümlülüklerini ( $14.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0IV3 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 0IV3 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 28.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0IV3 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 0IV3 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Geron Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Geron Corporation Appoints Joseph Eid as Executive Vice President, Research and Development

Third quarter 2024 earnings released: US$0.04 loss per share (vs US$0.077 loss in 3Q 2023)

Geron Corporation Announces New Data to Be Present at Upcoming ASH Annual Meeting Highlighting Potential of RYTELO (Imetelstat) in Myeloid Hematologic Malignancies

Geron Corporation to Report Q3, 2024 Results on Nov 07, 2024

Forecast to breakeven in 2026

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.09 loss in 2Q 2023)

Geron Corporation Announces Chief Commercial Officer to Depart, Effective August 31, 2024

Geron Corporation to Report Q2, 2024 Results on Aug 08, 2024

Geron Corporation Announces FDA Approval of RYTELO (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

First quarter 2024 earnings released: US$0.092 loss per share (vs US$0.07 loss in 1Q 2023)

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.37 loss in FY 2022)

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.077 loss per share (vs US$0.10 loss in 3Q 2022)

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.07 loss in 2Q 2022)

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Geron Corporation Announces Board Changes

First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.091 loss in 1Q 2022)

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in FY 2021)

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.081 loss in 3Q 2021)

Geron Corporation to Report Q3, 2022 Results on Nov 03, 2022

Geron Corporation Appoints John F. McDonald to Board of Directors

Geron Corporation Announces Update on Securities Class Action Lawsuit

Geron Corporation Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.09 loss in 2Q 2021)

Geron Corporation to Report Q2, 2022 Results on Aug 11, 2022

Geron Corporation Announces Executive Changes

Geron Corporation Announces Board Appointment

First quarter 2022 earnings released: US$0.091 loss per share (vs US$0.086 loss in 1Q 2021)

Geron Corporation to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

Insufficient new directors

Geron Corporation has completed a Follow-on Equity Offering.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $75 million.

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Geron Corporation to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.062 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.064 loss in 2Q 2020)

Geron Corporation Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology

Geron Reports Two Presentations At Virtual European Hematology Association Annual Congress

Forecast to breakeven in 2025

Geron Announces Two Presentations At Upcoming European Hematology Association Annual Congress

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.082 loss in 1Q 2020)

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.36 loss in FY 2019)

Revenue beats expectations

Geron Corporation to Report Q4, 2020 Results on Mar 11, 2021

Geron Corporation Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço